Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8; 21)

Blood

Volumn 87, Issue 3, 1996, Pages 1162-1169

  Porwit MacDonald, Anna ^b   Janossy, George ^a   Ivory, Kamal ^b   Swirsky, David ^b   Peters, Rowayda ^b   Wheatley, Keith ^b   Walker, Helen ^b   Turker, Alev ^b   Goldstone, Anthony H ^b   Burnett, Alan ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL STRUCTURE; CELL SYNCHRONIZATION; CHROMOSOME TRANSLOCATION 8; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIGENS, CD34; ANTIGENS, NEOPLASM; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; COHORT STUDIES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; LIFE TABLES; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030042827     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.1162.bloodjournal8731162     Document Type: Article

References (44)

1. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van den Berghe H, Bloomfield CD, de la Chappelle A, Dewald G, Garson OM: Long-term survival in acute myelogenous leukemia: A second follow-up of the 4th International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 73:1, 1994
2. Walker H, Smith SJ, Betts DR: Cytogenetics in acute myeloid leukaemia. Blood Rev 8:30, 1994
3. Nucifora G, Rowley JD: AML-1 and the (8;21) and (3;21) translocations in acute and chronic myeloid leukemias. Blood 86:1, 1994
4. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, Lo-Coco F, Diverio D, Pogliani EM, Lanzi EM: Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 80:492, 1992
5. Adriaansen HJ, Boekhorst PA, Hagemeijer AM, van der Schoot CE, Delwel HR, van-Dongen JJ: Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood 81:3043, 1993
6. Larripa I, Acevedo S, Palau-Nagore MV, Bengio R, Mondini N, Slavutsky I: Leukemic transformation in patients with 5Q- and additional abnormalities. Haematologica (Pavia) 76:363, 1991
7. Swirsky DM, Li YS, Matthews JG, Flemans RJ, Rees JK, Hayhoe FG: 8;21 Translocation in acute granulocytic leukaemia: Cytological, cytochemical and clinical features. Br J Haematol 56:199, 1984
8. Knapp W, Strobl H, Majidic O: Flow cytometric analysis of cell surface and intracellular antigens in leukemia diagnosis. Cytometry 18:187, 1994
9. Griffin JD, Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Beveridge RP, Schlossman SF: Surface marker analysis of acute myeloblastic leukemia: Identification of differentiation-associated phenotypes. Blood 62:57, 1983
10. Terstappen LW, Safford M, Loken MR: Flow cytometric analysis of human hone marrow. III. Neutrophil maturation. Leukemia 4:657, 1990
11. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB: Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 81:3083, 1993
12. Touw I, Donath J, Pouwels K, vanBuitenen C, Schipper P, Santini V, Hagemeijer A, Lowenberg B, Delwel R: Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5. Leukemia 5:687, 1991
13. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, Takakura N, Otsuji A, Shirakawa S, Ueda T: Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD 19 together with stem cell antigen CD34. Blood 80:470, 1992
14. Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro JJR, Kalwinsky DK, Ayers GD, Behm FG: Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 80:3182, 1992
15. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D: Surface marker expression in adult acute myeloid leukaemia: Correlations with initial characteristics, morphology and response to therapy. Br J Haematol 72.161, 1989
16. Coustan-Smith E, Behm FG, Hurwitz CA, Rivera GK, Campana D: N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 7:853, 1993
17. DiGiusto D, Chen S, Combs J, Webb S, Namikawa R, Tsukamolo A, Che BP, Galy AH: Human fetal bone marrow early progenitors for T, B and myeloid cells are found exclusively in the population expressing high levels of CD34. Blood 84:421, 1994
18. Strobl H, Takimoto M, Majdic O, Fritsch G, Scheinecker C, Hocker P, Knapp W: Myeloperoxidase expression in CD34+ normal human hematopoietic cells. Blood 82:2069, 1993
19. Vaughan WP, Civin CI, Weisenburger DD, Karp JE, Graham ML. Sanger WG, Grierson HL, Joshi SS, Burke PJ: Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia 2:661, 1988
20. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, Civin CI: Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: The significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 76:340, 1990
21. Solary E, Casasnovas RO, Campos L, Bene MC, Faure G, Maingon P, Falkenrodt A, Lenormand B, Genetet N: Surface markers in adult acute myeloblastic leukemia. Correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 6:393, 1992
22. Myint H, Lucie NP: The prognostic significance of the CD34 antigen in acute myeloid leukemia. Leuk Lymph 7:425, 1992
23. Marosi C, Koller U, Koller-Weber E, Schwarzinger I, Schneider B, Jager U, Vahls P, Nowotny H, Pirc-Danoewinata H, Steger G: Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 61:14, 1992
24. Schouten HC, van-Putten WL, Hagemeijer A, Blijham GH, Sonneveld P, Willemze R, Slater R, van Lely J, Verdonck LF, Lowenberg B: The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation. Bone Marrow Transplant 8:377, 1991
25. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620, 1985
26. Burnett AK, Goldstone AH, Hann IM, Stevens RF, Rees JKH, Wheatley K, Gray RG: Evaluation of autologous bone marrow transplantation in acute myeloid leukaemia: A progress report on the MRC Tenth AML Trial, in Dicke KA, Armitage JO (eds): Autologous Bone Marrow Transplantation, vol 5. Omaha, NE, University of Nebraska Medical Center, 1991, pp 3-7
27. Pizzolo G, Vincenzi C, Nadali G, Veneri D, Vinante F, Chilosi M, Basso G, Connelly MC, Janossy G: Detection of membrane and intracellular antigens by flow cytometry following Ortho Permeafix fixation. Leukemia 8:672, 1994
28. Poncelet P, Carayon P: Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Methods 85:65, 1985
29. Poncelet P, Poinas G, Corbeau P, Devaux C, Tubiana N, Muloko N, Tamalet C, Chermann JC, Kourilsky F, Sampol J: Surface CD4 density remains constant on lymphocytes of HIV-infected patients in the progression of disease. Res Immunol 142:291, 1991
30. Vogt RF, Marti GE, Schwarz A: Quantitative calibration of fluorescence intensity for clinical and research applications of immunophenotyping by flow cytometry. Rev Biotechnol Bioengineer 1:147, 1995
31. Campana D, Coustan-Smith E, Janossy G: The immunological detection of minimal residual disease in acute leukemia. Blood 76:163, 1990
32. Erickson PF, Robinson M, Owens G, Drabkin HA: The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionary conserved, putative transcription factor. Cancer Res 54:1782, 1994
33. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS: An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 81:2860, 1993
34. Lavabre-Bertrand T, Janossy G, Ivory K, Peters RE, Seeker-Walker L, Porwit-MacDonald A: Leukemia associated changes identified by quantitative flow cytometry. I. CD10 expression. Cytometry 18:209, 1994
35. Matutes E, Pombo De Oliviera MS, Foroni L, Morilla R, Catovsky D: The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia. Br J Haematol 69:205, 1988
36. Borowitz MJ, Gockerman JP, Moore JO, Civin CI, Page SO, Robertson J, Bigner SH: Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 91:265, 1989
37. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi G: Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymph 13:81, 1994
38. Fagioli F, Cuneo A, Carli MG, Bardi A, Piva N, Previati R, Rigolin GM, Ferrari L, Spanedda R, Castoldi G: Chromosome aberrations in CD34-positive acute myeloid leukemia. Correlation with clinicopathologic features. Cancer Genet Cytogenet 71:119, 1993
39. Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster Hill D, Noll W, Elghetany MT, Allen SL: Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 77:2242, 1991
40. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M: Analysis of CD7 expression in acute myelogenous leukemia: Martingale residual plots combined with optimal cutpoint analysis reveals absence of prognostic significance. Leukemia 9:1735, 1995
41. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B: AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735, 1994
42. Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H: Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 8:983, 1993
43. Nucifora G, Larson RA, Rowley JD: Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712, 1993
44. Maruyama F, Stass SA, Estey EH, Cork A, Hirano M, Ino T, Freireich EJ, Yang P, Chang KS: Detection of AML1/ETO fusion transcript as a tool for diagnosing 1(8;21) positive acute myelogenous leukemia. Leukemia 8:40, 1994